Drs. Vela and Adegunsoye share their insights into racial disparities in pulmonary fibrosis, including the impact of characterizing groups based on skin color or race, the concept of cultural humility, and best practices for diagnosing ILD while taking into account these disparities.

How does opioid prescribing in the ED differ between races? Find out about this and more in today's PeerDirect Medical News Podcast.

Drs. Gina Woods and Susan V. Bukata review surgical care, including joint replacement and spine surgery, in patients with osteoporosis. They discuss the planning and operative techniques that help improve outcomes in these patients.

Drs. Susan V. Bukata and Gina Woods discuss the perioperative care of patients with osteoporotic fractures and those with osteoporosis undergoing elective surgery.

Dr. Susan V. Bukata and Freda B. Hannafon, NP‑C, discuss the role of nurse practitioners and physician assistants in the care of patients with postmenopausal osteoporosis, including diagnosis, management, and collaboration with endocrinologists and orthopedic surgeons.

Drs. Mattingly and McIntyre continue their discussion about their insights into the role of emerging and novel mechanisms of action for potential treatments of schizophrenia, particularly those addressing the negative and cognitive symptoms.

Learn about OXO-001, a non-hormonal drug that increases pregnancy rates in women undergoing IVF or ICSI by enhancing embryo implantation. Also in this episode: patients with type 2 diabetes taking GLP-1 receptor agonists have a lower risk of certain obesity-associated cancers compared to those on insulin, though no significant reduction compared to metformin. Finally, the third story highlights research showing that smoking accelerates cognitive decline in memory and fluency, except for smokers with otherwise healthy lifestyles, who experience similar decline rates to non-smokers.

Drs. Roger McIntyre and Greg Mattingly share their insights into the role of emerging and novel mechanisms of action for potential treatments of schizophrenia, particularly those addressing the negative and cognitive symptoms.

In the second part of this series, Drs. Henry A. Nasrallah and Dawn Velligan continue sharing their insights into the importance of assessing and screening for cognitive impairment in patients with schizophrenia. They discuss why testing for cognitive impairment in standard clinical practice isn’t more widespread, the barriers clinicians face in testing, and the misconception that testing for cognitive impairment is prohibitive due to the resources required. Finally, they describe time factors and utility of several currently available tests, including those that can be used in busy ambulatory mental healthcare settings.

Drs. Dawn Velligan and Henry A. Nasrallah share their insights into the importance of assessing and screening for cognitive impairment in patients with schizophrenia. They discuss why testing for cognitive impairment in standard clinical practice isn’t more widespread, the barriers clinicians face in testing, and the misconception that testing for cognitive impairment is prohibitive due to the resources required. Finally, they describe time factors and utility of several currently available tests, including those that can be used in busy ambulatory mental healthcare settings.